JPS62292718A - Peroral drug preparation - Google Patents
Peroral drug preparationInfo
- Publication number
- JPS62292718A JPS62292718A JP61135561A JP13556186A JPS62292718A JP S62292718 A JPS62292718 A JP S62292718A JP 61135561 A JP61135561 A JP 61135561A JP 13556186 A JP13556186 A JP 13556186A JP S62292718 A JPS62292718 A JP S62292718A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- magnesium stearate
- magnesium
- formulation
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 38
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 28
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 24
- 239000000843 powder Substances 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- 239000011777 magnesium Substances 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- -1 troche Substances 0.000 abstract description 2
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000004503 fine granule Substances 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000007963 capsule composition Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical class CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Chemical class CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
３、発明の詳細な説明
〔産業上の利用分野〕
本発明は、イブプロフェン経口製剤に関し、さらに詳し
くはステアリン酸マグネ・／ラムを添加することを特徴
とする経口製剤に関する。Detailed Description of the Invention 3. Detailed Description of the Invention [Field of Industrial Application] The present invention relates to an oral preparation of ibuprofen, and more particularly to an oral preparation characterized by adding magne/lamb stearate. .
イブプロフェン〔２−（４−イソブチル）−プロピオン
酸＋ Ｃｌ５Ｈ１８０２（分子量、２ ｏ ６．２
ａ ） ２は非ステロイド系抗炎症剤で、１５・鎮痛、
解熱薬として広く用いられている。Ibuprofen [2-(4-isobutyl)-propionic acid + Cl5H1802 (molecular weight, 2 o 6.2
a) 2 is a non-steroidal anti-inflammatory drug, 15. Analgesic,
It is widely used as an antipyretic.
何ら処置をしない場合、イブプロフェン製７ｉ１１から
のイブプロフェ／の最高血中濃度到達時間（Ｔａ＝−ｘ
）は１．５〜６時間であり、〔塩用ら（診療と新薬、第
１８巻、第２１３９頁、１９８１年）〕速効性を必要と
する解熱鎮痛剤としては不十分である。If no treatment is taken, time to reach maximum blood concentration of ibuprofen from ibuprofen 7i11 (Ta=-x
) is 1.5 to 6 hours, which is insufficient for an antipyretic analgesic that requires rapid action [Shioyo et al. (Kyaku to Shinyaku, Vol. 18, p. 2139, 1981)].
このため、２対３のモル比でイブプロフェンをβ−７ク
ロデキストリンで包接することにより、Ｔｍ ａ Ｘ
を約２．５倍早める試みがなされた。〔チョウら、イ／
ターナ７ヨナル ジャーナル オスファーマ／ニーティ
、クス（工ｎｔ、 、Ｔ、 Ｐｈａｒｍ、 ＞第２８巻
、第９５頁、１９８６年〕
〔発明が解決しようとする問題点〕
しかしながら、この方法は分子量１０００を越えるβ−
７クロデキストリノをイブプロフェンにχすし、１，５
倍も加えてしまうと、製剤的に嵩高くなるという欠点が
ある。Therefore, by including ibuprofen with β-7 clodextrin in a molar ratio of 2:3, Tm a
An attempt was made to speed up the process by about 2.5 times. [Chou et al., Lee/
[Problems to be solved by the invention] However, this method has a molecular weight exceeding 1000. β-
7 clodextrino to ibuprofen χ sushi, 1,5
If the amount is doubled, there is a drawback that the formulation becomes bulky.
本発明の目的は最高血中濃度到達時間（Ｔｍａｘ）が短
いイブプロフェン経口製剤を提供することにある。An object of the present invention is to provide an oral preparation of ibuprofen that has a short time to reach maximum blood concentration (Tmax).
本発明者らは、上述の問題に鑑み、鋭意検討をは１０〜
５０重量％のステアリン酸マグネ７ウムを添加剤として
加えることによｐ、最高血中濃度到達時間（Ｔｍａｘ）
を早め、バイオアベイラビリティ−を高めることができ
た。すなわち、イブプロフェンに対し、ステアリン酸マ
グネシウムを１重量％添加したものではＴｍａｘおよび
血中濃度曲線上面積（ＡＵＣ）とも対照品と同等である
のに対し、５％添加するとＴｍａｘ が速くなり、吸収
が良くなる。さらに、３０重重量添加することにより、
Ｔｍａｘは対照品の約％時間となり、ＡＵＣは約２倍の
値を示した。ここでイブプロフェンに対シ、５％以上の
割合でステアリン酸マグネシウムを添加することによっ
て、速効性で、かつ、バイオアベイラビリティ−を高め
ることができた。In view of the above-mentioned problems, the present inventors have conducted intensive studies from 10 to 10.
By adding 50% by weight of magnesium stearate as an additive, the time to reach the maximum blood concentration (Tmax)
We were able to speed up the process and increase bioavailability. In other words, when 1% by weight of magnesium stearate is added to ibuprofen, Tmax and area on the blood concentration curve (AUC) are the same as the control product, but when 5% is added, Tmax becomes faster and absorption is reduced. Get better. Furthermore, by adding 30 wt.
Tmax was approximately % time of the control product, and AUC was approximately twice as high. Here, by adding magnesium stearate to ibuprofen at a ratio of 5% or more, it was possible to achieve rapid effect and increase bioavailability.
一方、配合割合の上限に関しては、特に制限するもので
はないが、イブプロフェンと同量を越えて配合すると、
製剤上嵩高くなってしまい、実用上、１回の投与量が増
すなどの問題を生じる。好−４しくは、イブプロフェン
に対し、５０重量％以下であり、この範囲内の添加量で
あれば、イブプロフェン製剤の吸収性を改良するだけで
なく、製剤設計上問題が無い。On the other hand, there is no particular restriction on the upper limit of the mixing ratio, but if it is added in excess of the same amount as ibuprofen,
The formulation is bulky, leading to practical problems such as an increase in the amount of one dose. Preferably, the amount is 50% by weight or less based on ibuprofen, and if the amount is within this range, it not only improves the absorbability of the ibuprofen preparation, but also causes no problems in formulation design.
本経口製剤を製造するに轟り、剤形を特に規定するもの
ではない。例えば、錠剤、丸剤、顆粒剤、細粒剤、散剤
、トローチ剤、カプセル剤などが挙げられる。The dosage form is not particularly specified due to the manufacturing process of the present oral preparation. Examples include tablets, pills, granules, fine granules, powders, troches, capsules, and the like.
ここでいうステアリン酸マグネシウムは、日本薬局方に
基づいたもの（成分的には、ステアリン酸とパルミチン
酸のマグネシウム塩の混合で、水晶を乾燥したものは、
３．９〜５，１重量％のマグネシウムを含有する。）で
もよい。The magnesium stearate mentioned here is based on the Japanese Pharmacopoeia (in terms of ingredients, it is a mixture of magnesium salts of stearic acid and palmitic acid, and dried crystals are
Contains 3.9-5.1% by weight of magnesium. ) is also fine.
本発明に係るステアリン酸マグネシウム配合イブプロフ
ェン製剤は、従来のものに比べ、速く薬効を発揮するこ
とができる。また従来のものと同等の薬効を発揮させる
だめのイブプロフェン配合量を少なくすることができる
ことから、潰瘍形成等の副作用を低減させるだけでなく
、製剤の小型化およびコストの低減をもたらす。The ibuprofen formulation containing magnesium stearate according to the present invention can exhibit its medicinal efficacy more quickly than conventional formulations. Furthermore, since it is possible to reduce the amount of ibuprofen that is required to exhibit the same medicinal efficacy as conventional drugs, it not only reduces side effects such as ulcer formation, but also results in smaller formulations and lower costs.
（実施例）
以下、実施例及び試験例をもって本発明を具体的に説明
する。(Examples) Hereinafter, the present invention will be specifically explained using Examples and Test Examples.
実施例 １
イブプロフェン １５０？、低置換度ヒドロキノフロビ
ルセルロース ７０ ？及ヒ乳糖７０ ？カら成る均質
な粉末混合物を調製し、常法により顆粒化した。別にス
テアリン酸マグネ７ウム７５？。Example 1 Ibuprofen 150? , low-substituted hydroquinoflovir cellulose 70? Orihi lactose 70? A homogeneous powder mixture was prepared and granulated in a conventional manner. Magnesium stearate 75? .
軽質無水ケイ酸４．５２を均質化した。２つの粉末混合
物を合わせ、さらにタルク１２． Ｏ？を加えて、混合
均質化したのち、常法によ、！７３号カプセル２０００
個に充填し、１カプセル当り以下に示す処方製剤を得た
。4.52 kg of light anhydrous silicic acid was homogenized. Combine the two powder mixtures and add 12. O? After adding and homogenizing, use the usual method! No. 73 capsule 2000
The following formulation was obtained per capsule.
イブプロフェン ７５００■ステアリ
ン酸マグネンウム ３．７５ ｍｇ低
置換Ｖヒト知キシプロピルセルロース ３５．００１
ｎ９乳 糖
３５． ＯＯｍｙ軽質無水ケイ酸
２．２５ ｍ９１５７、００〜
実施例 ２
実施例１記載の方法に従って、下記組成のカプセル裂創
を製造した。Ibuprofen 7500 ■ Magnenium stearate 3.75 mg Low substituted V human xypropyl cellulose 35.001
n9 lactose
35. OOmy light silicic anhydride
2.25 m9157, 00~ Example 2 According to the method described in Example 1, a capsule tear wound having the following composition was manufactured.
イブプロフェン ７５．００７１９ス
テアリン酸マグネ７ウム ２２．５０ｍ
９低置換度ヒドロキングロピルセルロース３５．００ｒ
ｎｑ乳 糖
３５゜ＯＯ巧軽質無水ケイ酸 ２．
２５ｍｑメルク ６．０
０ｍ９実施例 ６
ステアリン酸マグネ７ウム ＋ｏｏ？、ｐ質無水ケイ酸
６０？を混合し、均質化した。その後乳糖 ７４０？
、イブプロフェン ６００７、デンプン ７５０７を加
えて混合した。さらにビトロキシプロビルセルロース
ｓ ｏ ｔ Ｋｔｆｆｍ水５００ｍ１加えて溶解したも
のを結合剤として、混練したのち、常法に従って、１包
当り、以下の処方に示す顆粒剤２０００包を製造した。Ibuprofen 75.00719 Magnesium Stearate 22.50m
9 Low-substituted hydroquinlopylcellulose 35.00r
nq lactose
35゜OO fine light silicic anhydride 2.
25mq Merck 6.0
0m9 Example 6 Magnesium stearate +oo? , p-quality silicic anhydride 60? were mixed and homogenized. Then lactose 740?
, Ibuprofen 6007, and Starch 7507 were added and mixed. Furthermore bitroxyprobyl cellulose
After adding and dissolving 500 ml of s o t Ktffm water and kneading it as a binder, 2000 packages of granules having the following formulation were produced per package according to a conventional method.
イブプｏ７エ７ １５０．００１ｆｖステ
アリン酸マグネシウム ５０００〜デンプン
３７５．００〜乳糖 ｉ
７０・Ｏｏ即
軽質無水ケイ酸 ３０．００■ヒドロキシ
グロビルセルロース ２５． ＯＯ■実施例 ４
ステアリン酸マグネシウム ３００ ？、軽質無水ケイ
酸 １００り、乳糖 １２５０ｙ、イブプロフェン ３
００７を加えて混合した。ibupu o7e7 150.001fv Magnesium stearate 5000 ~ Starch 375.00 ~ Lactose i
70・Oo Instant light silicic anhydride 30.00■Hydroxyglobil cellulose 25. OO■Example 4 Magnesium stearate 300 ? , light silicic anhydride 100y, lactose 1250y, ibuprofen 3
007 was added and mixed.
サラニヒドロキ７プ口ビルセルロース ５０２に精製水
５００ｍ１加えて溶解したものを結合剤として混練し
、乾燥した。その後、常法に従って粉砕し、１包当り、
以下の処方に示す散剤２０００包を製造した。500 ml of purified water was added to and dissolved in Sarani Hydroki 7 Pucchivil Cellulose 502, which was then kneaded as a binder and dried. After that, it is crushed according to the usual method, and each package contains
2000 packets of the powder shown in the following formulation were manufactured.
イブプロフェン １５０．００■ステアリ
ン酸マグネシウム １５０．００■乳 糖
６２５．００■軽質無水
ケイ酸 ５０．００ηヒドロキシプロピ
ルセルロース ２５．００η１００α００Ｗｉ
実施例 ５
イブプロフェン １５０ｒ、低置換度ヒドロキ７グロビ
ルセルロース ７５７及び乳糖９０７から成る均質な粉
末混合物を調製し、常法により顆粒化した。別にステア
リン酸マグネシウム ２０７、軽質無水ケイ酸 １０２
を均質化した。２つの粉末混合物を合わせ、さらに、タ
ルク １５７を加えて混合均質化した後、常法により、
直径８の
咽５重量１８０Ａ７以下の処方に示す錠剤２０００錠を
打錠した。Ibuprofen 150.00■Magnesium stearate 150.00■Lactose 625.00■Light silicic anhydride 50.00ηHydroxypropyl cellulose 25.00η100α00Wi Example 5 From ibuprofen 150r, low substituted hydroxy-7 globilcellulose 757 and lactose 907 A homogeneous powder mixture was prepared and granulated in conventional manner. Separately, magnesium stearate 207, light silicic anhydride 102
was homogenized. After combining the two powder mixtures and mixing and homogenizing by adding talc 157,
2,000 tablets having a diameter of 8, a weight of 180 A7 or less were compressed.
イブプロフェン ７５．００■ステア
リン酸マグネシウム １０．００〜低置
換度ヒドロキシプａピルセルロース ５７．５０ｍｙ
乳 糖 ４５
． ＯＯ■軽質無水ケイ酸 ５．０
０■試験例
（試験薬剤）
対照薬剤：実施例１の記載の方法に従って、製造した下
記の組成のカプセル製剤。Ibuprofen 75.00■Magnesium stearate 10.00~Low substituted hydroxyl apyrucellulose 57.50my
Lactose 45
．． OO■Light silicic acid anhydride 5.0
0 ■Test Example (Test drug) Control drug: Capsule formulation manufactured according to the method described in Example 1 and having the following composition.
イブプロフェン ７５．００■低ｆ１
１１ｆｆｉヒドロキ／フロビルセルロース ２０００
■乳 糖 ２
０． ＯＯ■軽質無水ケイ酸 ２５．
００■タルク ６００グ１
４６．００■
試験製剤Ａ：実施例１の記載の方法に従って、製造した
下記組成のカプセル製剤。Ibuprofen 75.00■Low f1
11ffi Hydroxy/Flobil Cellulose 2000
■Lactose 2
0. OO■Light silicic anhydride 25.
00 ■ Talc 600g 1
46.00 ■ Test formulation A: A capsule formulation prepared according to the method described in Example 1 and having the following composition.
イブプロフェン ７５．００■ステア
リン酸マグネ７ウム ０７５η低ｉ換
ｉヒドロキ７プロビルセルロース ３５ａＯη乳
糖 ３５００■
軽質無水ケイ酸 ２．２５ｍｑタル
ク ６００■１５４．０
０ｍｑ
試験製剤Ｂ：実施例１のカプセル製剤。Ibuprofen 75.00■ Magnesium stearate 075η Low i-converted i-hydroxy-7 Probylcellulose 35aOη Milk
Sugar 3500■
Light anhydrous silicic acid 2.25mq talc 600■154.0
0 mq Test formulation B: Capsule formulation of Example 1.
試験製剤Ｃ：実施例２のカプセル製剤。Test formulation C: Capsule formulation of Example 2.
これら４つの製剤について雌性ピーグル犬各４頭を用い
て、バイオアベイラビリティ−評価を実施した。Bioavailability evaluation of these four formulations was conducted using four female pegle dogs each.
（方 法）
体重約１０に２の雌性ピーグル犬を投与前日より、１８
時間絶食させ、その後、試験製剤を水約１００ゴととも
に経口投与した。投与後の犬の状態は良好で吐くことは
なかった。(Method) A female peagle dog weighing approximately 10:2 and weighing 18
After fasting for an hour, the test formulation was orally administered along with approximately 100 grams of water. The dog was in good condition after administration and did not vomit.
採血は投与前、及び投与後、α５，１，２，３゜４．６
．８時間毎に前肢静脈より、ヘパリン処理注射筒にて行
なった。採血した血液は、３０００ｒｐｍで１０分間遠
心分離し、その血漿中のイブプロフェン１を高速液体ク
ロマトグラフづ一法により定量した。その結果を表１お
よび図１に示した。Blood was collected before and after administration at α5,1,2,3°4.6
．． Testing was performed every 8 hours via a forelimb vein using a heparinized syringe. The collected blood was centrifuged at 3000 rpm for 10 minutes, and ibuprofen 1 in the plasma was determined by high performance liquid chromatography. The results are shown in Table 1 and FIG.
、図、１は、実施例で調製した製剤および対照剤につい
てのバイオアベイラビリティ−試験結果を示す血中濃度
一時間特性図である。FIG. 1 is a blood concentration one-hour characteristic diagram showing the bioavailability test results for the preparations prepared in Examples and the control agent.
Claims (1)
リン酸マグネシウムを配合することを特徴とする経口製
剤。1) An oral preparation characterized in that 5 to 100% by weight of magnesium stearate is blended with ibuprofen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135561A JPS62292718A (en) | 1986-06-11 | 1986-06-11 | Peroral drug preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135561A JPS62292718A (en) | 1986-06-11 | 1986-06-11 | Peroral drug preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62292718A true JPS62292718A (en) | 1987-12-19 |
| JPH0560810B2 JPH0560810B2 (en) | 1993-09-03 |
Family
ID=15154688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61135561A Granted JPS62292718A (en) | 1986-06-11 | 1986-06-11 | Peroral drug preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62292718A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
| JP2005035995A (en) * | 2003-07-01 | 2005-02-10 | Sankyo Co Ltd | Ibuprofen-containing oral composition |
| JP2011052023A (en) * | 2003-07-01 | 2011-03-17 | Daiichi Sankyo Healthcare Co Ltd | Ibuprofen-containing oral composition |
| AT511581A1 (en) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | ORAL RETARDANT FORMULATION |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56154416A (en) * | 1980-04-30 | 1981-11-30 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
-
1986
- 1986-06-11 JP JP61135561A patent/JPS62292718A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56154416A (en) * | 1980-04-30 | 1981-11-30 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
| JP2005035995A (en) * | 2003-07-01 | 2005-02-10 | Sankyo Co Ltd | Ibuprofen-containing oral composition |
| JP2011052023A (en) * | 2003-07-01 | 2011-03-17 | Daiichi Sankyo Healthcare Co Ltd | Ibuprofen-containing oral composition |
| AT511581A1 (en) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | ORAL RETARDANT FORMULATION |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0560810B2 (en) | 1993-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200323776A1 (en) | Diclofenac formulations and methods of use | |
| US5211958A (en) | Pharmaceutical composition and process for its preparation | |
| IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JPH07112973B2 (en) | Soluble anti-inflammatory composition containing ibuprofen or a salt thereof as an active material and method for producing the same | |
| JPH05505193A (en) | drug formulation | |
| JPH0717866A (en) | Medicinal composition | |
| JP2879905B2 (en) | Composition for oral administration containing ibuprofen | |
| JPS62292718A (en) | Peroral drug preparation | |
| PT85871B (en) | Process for the preparation of orally administrable pharmaceutical compositions which contain chenodeoxycholic acid or deoxycholic acid or a salt of either of these acids any of wich may be used alone or is combination with a synergist | |
| FI89240C (en) | ANVAENDNING AV TILLSATSMEDEL FOER OEKNING AV IBUPROFENS ABSORPTIONSHASTIGHET | |
| JPS63107933A (en) | Production of preparation of aluminum salt of sucrose sulfuric acid ester | |
| IE883560L (en) | Tetracycline tablet | |
| JPS6357521A (en) | Oral preparation | |
| JP3947244B2 (en) | Preparation for peptic ulcer treatment | |
| JP3202775B2 (en) | Solid preparation | |
| JPH1045580A (en) | Production of carnitine chloride-containing pharmaceutical preparation | |
| WO2003070217A1 (en) | Levothyroxine compositions and methods | |
| JPH0426624A (en) | Remedy for chronic renal failure | |
| JPH02206A (en) | Novel drug preparation containing exifone and water-soluble polymeric compound | |
| JPH09309829A (en) | Oral administration preparation containing nitrendipine and its production | |
| CA2174538A1 (en) | Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation | |
| JPS6360926A (en) | Cold remedy | |
| JPH02207A (en) | Drug preparation containing bromhexine hydrochloride | |
| JPH0129169B2 (en) | ||
| WO1996025158A1 (en) | Medicinal composition containing azulene derivative and process for producing the same |